Based: San Diego
Raised: $53 million
Investors: Enterprise Partners Venture Capital, GBS Venture Partners, H&Q Healthcare Investors, Hambrecht & Quist Capital Management, Johnson & Johnson Development Corporation, Lundbeckfond Ventures, MPM Capital, Novartis Venture Funds, Pfizer Venture Investments, Venrock Associates, and an undisclosed investor.

The scoop: The money is being used to engineer late-stage work on Mydicar, a heart failure treatment that recently gained fast-track status at the FDA. It also marks a major milestone for Celladon, which announced 5 years ago that it had raised $30 million from Kleiner Perkins and others to get Mydicar into the clinic.

Editor's note: This story has been updated with new information from Thomson Reuters.


Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.